U.S. Healthtech Stock News

Why PNC Financial Services Group Stock Is On Investors’ Radar PNC Financial Services Group (PNC) has drawn attention after recent trading left the shares about 5% lower over the past month and roughly 4% lower over the past 3 months. That short term softness comes against a backdrop of reported revenue of US$22,320.0m and net income of US$6,576.0m. These figures provide a starting point to think about how the current share price might line up with the company’s scale and profitability. See...

Zimmer Biomet awards highlight focus on orthopedic tech and digital tools Zimmer Biomet Holdings (ZBH) has drawn fresh investor interest after receiving three Healthcare Asia Medtech Awards 2026, recognizing its iodine-treated hip implants and WalkAI recovery monitoring platform, alongside broader orthopedic and surgeon engagement capabilities. See our latest analysis for Zimmer Biomet Holdings. Despite recognition for its orthopedic and digital health tools, Zimmer Biomet’s recent share...

IonQ (NYSE:IONQ) has entered a definitive agreement to acquire SkyWater Technology in a deal valued at US$1.8b. The transaction deepens IonQ’s control over its quantum hardware supply chain by bringing a semiconductor and foundry partner in house. This move is positioned to support IonQ’s efforts toward commercially viable, fault tolerant quantum computing. For readers tracking quantum computing, IonQ is one of the better known pure play names, focused on building trapped ion quantum...

Haemonetics Corporation recently received U.S. Food and Drug Administration approval to expand labeling for its VASCADE MVP XL venous vascular closure system to cover larger 10–14F inner diameter and up to 17F outer diameter procedural sheaths used in pulsed field ablation and left atrial appendage closure for atrial fibrillation. This decision, backed by the AMBULATE EXPAND trial showing no major or minor access site closure-related complications and rapid ambulation, strengthens...

If you are wondering whether nLIGHT's share price still reflects its underlying value, it helps to step back from the excitement and look closely at what the numbers actually say. The stock trades at US$53.98 after a 40.7% return year to date, which comes on top of a very large 1 year gain and a 438.7% return over 3 years, despite a recent 22.8% 7 day pullback and a modest 3.9% 30 day decline. Recent coverage has focused on nLIGHT's position in high performance laser technology and its role...

Earlier in March 2026, Casella Waste Systems, Inc. appointed Christopher A. Rains as Senior Vice President and Chief Revenue Officer, adding a leader with more than two decades of commercial, operational, and customer-focused experience across major waste management and industrial companies. Rains’ combination of industry depth, Lean Six Sigma Black Belt training, and proven work on complex organizational transformations introduces fresh commercial leadership that could influence how Casella...

Papa John’s International recently launched Oven-Toasted Sandwiches on toasted ciabatta-style bread, featuring high-quality meats, white American cheese, new signature sauces, and bundle pricing starting at US$7.99. This move extends Papa John’s beyond its traditional pizza focus, using premium, garlic-sauce-brushed sandwiches to try to refresh demand amid weak same-store sales and higher operating costs. Next, we’ll consider how this push into indulgent, garlic-brushed Oven-Toasted...

In March 2026, Comstock Resources announced that its Western Haynesville operations will host the Texas Natural Gas-Fired Power Generation Hub in Anderson County, a U.S.-Japan joint project to be built and operated by NextEra Energy under the countries’ trade agreement framework. Alongside U.S. approval for NextEra Energy to develop up to 10 gigawatts of natural gas-powered generation in Texas and Pennsylvania, these projects expand the company’s role in large-scale, reliability-focused...

Apogee Therapeutics recently reported positive 52-week Phase 2 APEX trial data for its lead anti-IL-13 antibody zumilokibart in moderate-to-severe atopic dermatitis, alongside completing a follow-on common stock offering of about US$403,000,000 at US$70 per share. The maintenance data suggest zumilokibart may offer durable disease control with 3- or 6-month dosing intervals, a dosing schedule that could meaningfully differentiate it from existing atopic dermatitis treatments if later-stage...

Middleby stock performance and recent context Middleby (MIDD) has been under pressure recently, with the share price showing negative returns over the past week, month and past 3 months, prompting investors to reassess how its current valuation lines up with the underlying business. See our latest analysis for Middleby. The recent 24.68% 30 day share price decline, alongside a 16.31% 1 year total shareholder return decline, suggests momentum has faded and investors are reassessing Middleby at...

In March 2026, T-Mobile US saw board member Abdurazak Mudesir resign, while partners McGraw Hill, NVIDIA and Infobip announced new collaborations that pair T-Mobile’s 5G network and APIs with digital education, edge AI and security solutions. Together, these moves highlight how T-Mobile is seeking to extend its role beyond core wireless access into education technology, physical AI infrastructure and enterprise identity verification. Now we’ll examine how T-Mobile’s push into 5G-powered...

In March 2026, Protagonist Therapeutics reported one-year Phase 3 data for ICOTYDE (icotrokinra) in moderate to severe plaque psoriasis, showing sustained skin clearance and a favorable safety profile as the first oral IL-23 receptor–targeted peptide. The data, including adolescent results through Week 52, underline ICOTYDE’s potential as a once-daily pill alternative to injectable treatments and highlight the company’s peptide discovery platform. We’ll now look at how ICOTYDE’s...

What Schwab’s Teen Investor Account Means for the Business Charles Schwab (SCHW) is expanding deeper into youth investing with its new Schwab Teen Investor account, a joint brokerage structure aimed at 13 to 17 year olds and their parents. The launch ties financial education, low cost trading access, and small fractional share incentives together. This raises questions for investors about how early life relationships could fit into Schwab’s long term client growth story. See our latest...

Event context and recent price performance Biglari Holdings (BH.A) recently caught investor attention after a 3% move in the latest session, contrasting with a decline of about 17% over the past month and a smaller pullback over the past 3 months. See our latest analysis for Biglari Holdings. That recent 3% daily share price move sits against a weaker short term trend, with a 30 day share price return of about a 17% decline. However, the 1 year total shareholder return of 50.73% and 5 year...

Mother’s Day collaboration puts Bath & Body Works stock in focus Bath & Body Works (BBWI) is drawing fresh investor attention after unveiling a Vera Bradley collaboration for Mother’s Day, a limited-edition collection that spans body care, home fragrance, decor and accessories. See our latest analysis for Bath & Body Works. That Mother’s Day launch lands at a time when the 1-day share price return of 11.13% stands in contrast to a 30-day share price return decline of 17.97% and a 1-year total...

In the first quarter ended February 28, 2026, KB Home reported lower sales and net income year over year, while also completing a US$150 million share repurchase totaling 2,397,196 shares under its October 2025 authorization. At the same time, management issued revenue guidance for the second quarter and full year 2026 that frames housing revenues within a relatively tight range, underscoring a cautious demand outlook despite continued capital returns. Next, we will examine how KB Home’s...

At the March 12, 2026 BofA Securities Information & Business Services Conference, First Advantage Corporation highlighted 17% fourth-quarter revenue growth, a transition toward capital risk management solutions, and board approval of a US$100,000,000 share repurchase program. The company’s emphasis on expanding beyond background screening into a broader capital risk management platform, supported by about 97% client retention, underlines management’s confidence in scaling the business...

Relay Therapeutics (RLAY) is back in focus after releasing new Phase 1/2 ReDiscover trial data for zovegalisib plus fulvestrant in PI3Ka-mutated, HR+/HER2- metastatic breast cancer, supporting its selected Phase 3 dosing regimen. See our latest analysis for Relay Therapeutics. The latest trial update comes after a sharp move in the stock, with a 1 day share price return of negative 5.14% and a 30 day share price return of negative 6.43%. However, a 1 year total shareholder return of 266.41%...

Recently, Globant and PharmaMar announced a collaboration to apply Globant Enterprise AI in accelerating cancer drug discovery, while Globant and Adyen formalized a global partnership making Globant a lead integration partner for Adyen’s payments platform. Together, these alliances show how Globant is embedding its AI and integration capabilities at the core of critical workflows in both healthcare R&D and global payments infrastructure. Now we’ll examine how Globant’s AI-powered PharmaMar...

With no single headline event driving Allegion (ALLE) into focus, investors are instead looking at the stock's recent performance and fundamentals, including its US$4,067.3m in revenue and US$643.8m in net income. See our latest analysis for Allegion. Allegion’s recent share price performance has been soft, with a 1-month share price return of 10.33% and a year to date share price return of 10.2%. The 1-year total shareholder return sits at 12.27%, which hints at longer term holders faring...

Schneider National (SNDR) recently reported quarterly results, with revenue up 4.5% year on year but below analyst expectations, and full-year EPS guidance also under forecasts. This combination has coincided with a 13.5% decline in the share price. See our latest analysis for Schneider National. At a share price of $25.44, Schneider National’s 30 day share price return of 10.36% and 90 day share price return of 5.25% sit against a 1 year total shareholder return of 13.07%. This indicates...

Global Partners (GLP) has drawn investor attention after its recent share moves, with the stock closing at US$44.37. That price appears alongside mixed recent returns and a value score of 3. See our latest analysis for Global Partners. The recent pullback, with a 1-day share price return of 1.40% decline and a 7-day share price return of 4.42% decline, contrasts with a 90-day share price return of 3.98% and multi year total shareholder returns that remain strongly positive. This points to...

Kennametal (KMT) is back on investors’ radar after its consensus EPS estimate for the current year moved 56.8% higher in the past 3 months, alongside an upgrade to Zacks Rank #1. See our latest analysis for Kennametal. The share price has moved to US$36.08 after a 25.93% 90 day share price return. The 1 year total shareholder return of 74.83% contrasts with a recent 10.43% 1 month share price decline, suggesting that momentum has cooled after a strong run. If this kind of swing in sentiment...

On March 23, Sensient Food Colors, a division of Sensient Technologies, marked the start of “Project Prism,” a major expansion of its largest natural color plant in St. Louis, Missouri, as part of a planned US$250 million program to grow capacity, supply chain and workforce. This expansion underlines how Sensient is committing significant long-term capital to meet rising demand for natural food colors as brands move away from artificial additives. Next, we’ll examine how Project Prism’s...